Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
- Associated Therapies
- -
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT02507479
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Tel-Hashomer, Israel
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2024-07-29
- Target Recruit Count
- 76
- Registration Number
- NCT02329080
- Locations
- 🇮🇹
IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
🇮🇹Villa Sofia - Cervello, Palermo, Italy
🇨🇿Facultni nemocnice, Brno, Czechia
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
- Conditions
- Interventions
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02259348
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDonorRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaChildhood Acute Myeloid Leukemia in RemissionMyelodysplastic Syndrome With Excess Blasts-2Recurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: Mycophenolate MofetilDrug: MethotrexateProcedure: Peripheral Blood Stem Cell TransplantationDrug: TacrolimusDrug: ThiotepaRadiation: Total-Body Irradiation
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 84
- Registration Number
- NCT02220985
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
- Conditions
- Interventions
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT02199041
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Diane George
- Target Recruit Count
- 14
- Registration Number
- NCT02061800
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Istituto Clinico Humanitas
- Target Recruit Count
- 47
- Registration Number
- NCT02049580
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, MI, Italy
Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 29
- Registration Number
- NCT02025881
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷Centre Oscar Lambret, Lille, France
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- Conditions
- Interventions
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 100
- Registration Number
- NCT01962415
- Locations
- 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- St. Anna Kinderkrebsforschung
- Target Recruit Count
- 1800
- Registration Number
- NCT01949129
- Locations
- 🇦🇷
Hospital Sor Maria Ludovica, Department Hematology Stem Cell Transplant Unit, La Plata, Argentina
🇧🇪University Hospitals Leuven Kinderhemato-oncologie, Leuven, Belgium
🇮🇱Dana Children's Hospital, Tel Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.